Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

Alessandra Iurlo, Sara Galimberti, Elisabetta Abruzzese, Mario Annunziata, Massimiliano Bonifacio, Roberto Latagliata, Patrizia Pregno, Dario Ferrero, Federica Sorà, Ester Maria Orlandi, Carmen Fava, Daniele Cattaneo, Cristina Bucelli, Gianni Binotto, Ester Pungolino, Mario Tiribelli, Antonella Gozzini, Gabriele Gugliotta, Fausto Castagnetti, Fabio StagnoGiovanna Rege-Cambrin, Bruno Martino, Luigiana Luciano, Massimo Breccia, Simona Sica, Monica Bocchia, Fabrizio Pane, Giuseppe Saglio, Gianantonio Rosti, Giorgina Specchia, Agostino Cortelezzi, Michele Baccarani

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Pleural effusion (PE) represents the leading cause of dasatinib (DAS) discontinuation. However, the pathogenic mechanism of this adverse event (AE) is unknown and its management unclear. We investigated if a DAS dose reduction after the first PE would prevent the recurrence of this AE. We retrospectively collected data on all the cases of PE in CML-chronic phase (CP) DAS-treated patients from November 2005 to February 2017 in 21 Italian hematological centers. We identified 196 cases of PE in a series of 853 CML-CP DAS-treated patients (incidence 23.0%). DAS starting dose was 100 mg/day in 70.4% of patients, less than 100 mg/day in 14.3%, and more than 100 mg/day in the remaining cases. Median time from DAS start to PE was 16.6 months. At first PE development, 28.6% of patients were in MMR, and 37.8% in deep molecular response (DMR). DAS was temporary interrupted in 71.9% of cases, with a dose reduction in 59.2%. Recurrence was observed in 59.4% of the cases. Treatment was definitively discontinued due to PE in 29.1% of the cases. Interestingly, among patients whose DAS dosage was reduced, 59.5% experienced PE recurrence. DAS dose reduction after the first episode of PE did not prevent recurrence of this AE. Therefore, once a MMR or a DMR is achieved, different strategies of DAS dose management can be proposed prior to the development of PE, such as daily dose reduction or, as an alternative option, an on/off treatment with a weekend drug holiday.

Original languageEnglish
Pages (from-to)95-100
Number of pages6
JournalAnnals of Hematology
Volume97
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Pleural Effusion
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Recurrence
Dasatinib
Holidays
Incidence

Keywords

  • Chronic myeloid leukemia
  • Dasatinib
  • Dose reduction
  • Molecular response
  • Pleural effusion

ASJC Scopus subject areas

  • Hematology

Cite this

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. / Iurlo, Alessandra; Galimberti, Sara; Abruzzese, Elisabetta; Annunziata, Mario; Bonifacio, Massimiliano; Latagliata, Roberto; Pregno, Patrizia; Ferrero, Dario; Sorà, Federica; Orlandi, Ester Maria; Fava, Carmen; Cattaneo, Daniele; Bucelli, Cristina; Binotto, Gianni; Pungolino, Ester; Tiribelli, Mario; Gozzini, Antonella; Gugliotta, Gabriele; Castagnetti, Fausto; Stagno, Fabio; Rege-Cambrin, Giovanna; Martino, Bruno; Luciano, Luigiana; Breccia, Massimo; Sica, Simona; Bocchia, Monica; Pane, Fabrizio; Saglio, Giuseppe; Rosti, Gianantonio; Specchia, Giorgina; Cortelezzi, Agostino; Baccarani, Michele.

In: Annals of Hematology, Vol. 97, No. 1, 01.01.2018, p. 95-100.

Research output: Contribution to journalArticle

Iurlo, A, Galimberti, S, Abruzzese, E, Annunziata, M, Bonifacio, M, Latagliata, R, Pregno, P, Ferrero, D, Sorà, F, Orlandi, EM, Fava, C, Cattaneo, D, Bucelli, C, Binotto, G, Pungolino, E, Tiribelli, M, Gozzini, A, Gugliotta, G, Castagnetti, F, Stagno, F, Rege-Cambrin, G, Martino, B, Luciano, L, Breccia, M, Sica, S, Bocchia, M, Pane, F, Saglio, G, Rosti, G, Specchia, G, Cortelezzi, A & Baccarani, M 2018, 'Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series', Annals of Hematology, vol. 97, no. 1, pp. 95-100. https://doi.org/10.1007/s00277-017-3144-1
Iurlo, Alessandra ; Galimberti, Sara ; Abruzzese, Elisabetta ; Annunziata, Mario ; Bonifacio, Massimiliano ; Latagliata, Roberto ; Pregno, Patrizia ; Ferrero, Dario ; Sorà, Federica ; Orlandi, Ester Maria ; Fava, Carmen ; Cattaneo, Daniele ; Bucelli, Cristina ; Binotto, Gianni ; Pungolino, Ester ; Tiribelli, Mario ; Gozzini, Antonella ; Gugliotta, Gabriele ; Castagnetti, Fausto ; Stagno, Fabio ; Rege-Cambrin, Giovanna ; Martino, Bruno ; Luciano, Luigiana ; Breccia, Massimo ; Sica, Simona ; Bocchia, Monica ; Pane, Fabrizio ; Saglio, Giuseppe ; Rosti, Gianantonio ; Specchia, Giorgina ; Cortelezzi, Agostino ; Baccarani, Michele. / Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. In: Annals of Hematology. 2018 ; Vol. 97, No. 1. pp. 95-100.
@article{c95d1b29eab648f78305f9ea2622fb36,
title = "Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series",
abstract = "Pleural effusion (PE) represents the leading cause of dasatinib (DAS) discontinuation. However, the pathogenic mechanism of this adverse event (AE) is unknown and its management unclear. We investigated if a DAS dose reduction after the first PE would prevent the recurrence of this AE. We retrospectively collected data on all the cases of PE in CML-chronic phase (CP) DAS-treated patients from November 2005 to February 2017 in 21 Italian hematological centers. We identified 196 cases of PE in a series of 853 CML-CP DAS-treated patients (incidence 23.0{\%}). DAS starting dose was 100 mg/day in 70.4{\%} of patients, less than 100 mg/day in 14.3{\%}, and more than 100 mg/day in the remaining cases. Median time from DAS start to PE was 16.6 months. At first PE development, 28.6{\%} of patients were in MMR, and 37.8{\%} in deep molecular response (DMR). DAS was temporary interrupted in 71.9{\%} of cases, with a dose reduction in 59.2{\%}. Recurrence was observed in 59.4{\%} of the cases. Treatment was definitively discontinued due to PE in 29.1{\%} of the cases. Interestingly, among patients whose DAS dosage was reduced, 59.5{\%} experienced PE recurrence. DAS dose reduction after the first episode of PE did not prevent recurrence of this AE. Therefore, once a MMR or a DMR is achieved, different strategies of DAS dose management can be proposed prior to the development of PE, such as daily dose reduction or, as an alternative option, an on/off treatment with a weekend drug holiday.",
keywords = "Chronic myeloid leukemia, Dasatinib, Dose reduction, Molecular response, Pleural effusion",
author = "Alessandra Iurlo and Sara Galimberti and Elisabetta Abruzzese and Mario Annunziata and Massimiliano Bonifacio and Roberto Latagliata and Patrizia Pregno and Dario Ferrero and Federica Sor{\`a} and Orlandi, {Ester Maria} and Carmen Fava and Daniele Cattaneo and Cristina Bucelli and Gianni Binotto and Ester Pungolino and Mario Tiribelli and Antonella Gozzini and Gabriele Gugliotta and Fausto Castagnetti and Fabio Stagno and Giovanna Rege-Cambrin and Bruno Martino and Luigiana Luciano and Massimo Breccia and Simona Sica and Monica Bocchia and Fabrizio Pane and Giuseppe Saglio and Gianantonio Rosti and Giorgina Specchia and Agostino Cortelezzi and Michele Baccarani",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s00277-017-3144-1",
language = "English",
volume = "97",
pages = "95--100",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

AU - Iurlo, Alessandra

AU - Galimberti, Sara

AU - Abruzzese, Elisabetta

AU - Annunziata, Mario

AU - Bonifacio, Massimiliano

AU - Latagliata, Roberto

AU - Pregno, Patrizia

AU - Ferrero, Dario

AU - Sorà, Federica

AU - Orlandi, Ester Maria

AU - Fava, Carmen

AU - Cattaneo, Daniele

AU - Bucelli, Cristina

AU - Binotto, Gianni

AU - Pungolino, Ester

AU - Tiribelli, Mario

AU - Gozzini, Antonella

AU - Gugliotta, Gabriele

AU - Castagnetti, Fausto

AU - Stagno, Fabio

AU - Rege-Cambrin, Giovanna

AU - Martino, Bruno

AU - Luciano, Luigiana

AU - Breccia, Massimo

AU - Sica, Simona

AU - Bocchia, Monica

AU - Pane, Fabrizio

AU - Saglio, Giuseppe

AU - Rosti, Gianantonio

AU - Specchia, Giorgina

AU - Cortelezzi, Agostino

AU - Baccarani, Michele

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Pleural effusion (PE) represents the leading cause of dasatinib (DAS) discontinuation. However, the pathogenic mechanism of this adverse event (AE) is unknown and its management unclear. We investigated if a DAS dose reduction after the first PE would prevent the recurrence of this AE. We retrospectively collected data on all the cases of PE in CML-chronic phase (CP) DAS-treated patients from November 2005 to February 2017 in 21 Italian hematological centers. We identified 196 cases of PE in a series of 853 CML-CP DAS-treated patients (incidence 23.0%). DAS starting dose was 100 mg/day in 70.4% of patients, less than 100 mg/day in 14.3%, and more than 100 mg/day in the remaining cases. Median time from DAS start to PE was 16.6 months. At first PE development, 28.6% of patients were in MMR, and 37.8% in deep molecular response (DMR). DAS was temporary interrupted in 71.9% of cases, with a dose reduction in 59.2%. Recurrence was observed in 59.4% of the cases. Treatment was definitively discontinued due to PE in 29.1% of the cases. Interestingly, among patients whose DAS dosage was reduced, 59.5% experienced PE recurrence. DAS dose reduction after the first episode of PE did not prevent recurrence of this AE. Therefore, once a MMR or a DMR is achieved, different strategies of DAS dose management can be proposed prior to the development of PE, such as daily dose reduction or, as an alternative option, an on/off treatment with a weekend drug holiday.

AB - Pleural effusion (PE) represents the leading cause of dasatinib (DAS) discontinuation. However, the pathogenic mechanism of this adverse event (AE) is unknown and its management unclear. We investigated if a DAS dose reduction after the first PE would prevent the recurrence of this AE. We retrospectively collected data on all the cases of PE in CML-chronic phase (CP) DAS-treated patients from November 2005 to February 2017 in 21 Italian hematological centers. We identified 196 cases of PE in a series of 853 CML-CP DAS-treated patients (incidence 23.0%). DAS starting dose was 100 mg/day in 70.4% of patients, less than 100 mg/day in 14.3%, and more than 100 mg/day in the remaining cases. Median time from DAS start to PE was 16.6 months. At first PE development, 28.6% of patients were in MMR, and 37.8% in deep molecular response (DMR). DAS was temporary interrupted in 71.9% of cases, with a dose reduction in 59.2%. Recurrence was observed in 59.4% of the cases. Treatment was definitively discontinued due to PE in 29.1% of the cases. Interestingly, among patients whose DAS dosage was reduced, 59.5% experienced PE recurrence. DAS dose reduction after the first episode of PE did not prevent recurrence of this AE. Therefore, once a MMR or a DMR is achieved, different strategies of DAS dose management can be proposed prior to the development of PE, such as daily dose reduction or, as an alternative option, an on/off treatment with a weekend drug holiday.

KW - Chronic myeloid leukemia

KW - Dasatinib

KW - Dose reduction

KW - Molecular response

KW - Pleural effusion

UR - http://www.scopus.com/inward/record.url?scp=85039838668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039838668&partnerID=8YFLogxK

U2 - 10.1007/s00277-017-3144-1

DO - 10.1007/s00277-017-3144-1

M3 - Article

AN - SCOPUS:85039838668

VL - 97

SP - 95

EP - 100

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 1

ER -